RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing alternative treatments for conditions ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) gains attention across Nasdaq index fund holdings after upgrade and strong quarterly performance.

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

University of Queensland research has revealed that double-stranded RNA-based biopesticides (dsRNA) sprayed on plant leaves ...

Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological ...

The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain ...

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...

Irish biotech Aerska raises €32M to deliver RNA medicines to the brain, targeting Alzheimer’s and Parkinson’s at their ...

Madrigal is eying an expansion of MASH blockbuster Rezdiffra’s capabilities via combination with precision siRNA gene ...

Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.

Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today ...

Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025Appoints Arno de Wilde, Philip Scheltens and Alex Colville to its Board of Directors ...